256 - Safety and Efficacy of the LOBO® Vascular Occlusion Device for Embolization of Pulmonary Arteriovenous Malformations (PAVM): A Single-Center Experience

Tuesday, April 14, 2026

3:00 PM - 3:09 PM ET

Presenting Author(s)

RV

Roshan Valentine, MD, MBBS

Fellow in Interventional Oncology
Division of Vascular & Interventional Radiology, Department of Radiology, University of North Carolina at Chapel Hill, United States

Author/Co-author(s)

Jd

Johannes du Pisanie, Jr., MD (he/him/his)

Integrated Interventional Radiology Resident
UNC School of Medicine, United States
Michael Mohnasky, MS (he/him/his)

Medical Student
UNC School of Medicine, United States
Sandra Gad

Medical Student
SGU, United States
BW

Baxter Williams, MD

Resident
Division of Vascular & Interventional Radiology, Department of Radiology, University of North Carolina at Chapel Hill,University of North Carolina at Chapel Hill, United States
BB

Benjamin Brown, MD, MPH

Resident Physician
University of North Carolina - Chapel Hill - Department of Interventional Radiology, United States
DM

David Mauro, MD

Associate Professor
University of North Carolina, United States
Ali Afrasiabi, MD

Postdoctoral Researcher
University of North Carolina - Chapel Hill - Department of Interventional Radiology, United States
BG

Bahareh Gholami, MD

Post doctoral research scholar
University of North Carolina, United States
KS

Karen Smith, RN

Registered Nurse
Division of Vascular & Interventional Radiology, Department of Radiology, University of North Carolina at Chapel Hill,University of North Carolina at Chapel Hill, United States
RK

Raj Kasthuri, MD

Hematologist
Associate Professor of Medicine in the Division of Hematology and Oncology, United States
Nima Kokabi, MD

Associate Professor of Radiology
University of North Carolina - Chapel Hill, United States

Purpose: To assess the safety, technical success, and medium-term clinical efficacy of the Low Profile Braided Occluder (LOBO) device (Okami Medical, Aliso Viejo, California) for embolization of pulmonary arteriovenous malformations (PAVMs).

Materials and Methods: A single-center retrospective study of consecutive patients with PAVMs who underwent transcatheter embolization using LOBO devices was performed. Technical success was defined as complete occlusion of the intended feeding artery with a single LOBO device. Procedure time and radiation to the patient were also recorded. Clinical efficacy was defined as the absence of recanalization/persistence of embolized PAVM and ≥70% reduction in sac size on 6-month follow-up CT angiography (CTA) {1}. Additionally, complications/adverse events were assessed following embolization using the Society of Interventional Radiology Classification {2}.

Results: Twenty-three patients (mean age 42.3 years; 82% female) were treated, of whom 87% had Hereditary Hemorrhagic Telangiectasia.Overall, 55 PAVMs in the patients included in our study were embolized; of these, 52 were simple PAVMs (i.e., with a single feeding artery), while 3 were complex PAVMs (i.e., with multiple feeding arteries) supplied by 7 feeding arteries cumulatively. All arteries were embolized using a single device per feeder (LOBO-3, n=37; LOBO-5, n=18; LOBO-7, n=3; LOBO-9, n=1) with no additional embolic devices required. Mean feeding artery diameter was 2.93 mm (SD:1.05, Range:1.6-7.0). The mean fluoroscopy time was 29.19 minutes (SD: 18.38), and the mean radiation dose was 623.5 mGy. Technical success was 100%, with no intraprocedural device mal-deployment or migration. At median imaging follow-up of 6 months (Median 266 days, Range 154 - 474 days), there was no recanalization of treated arterial feeders and no persistence or recanalization of the PAVM sac on CTA. No device-related complications, pulmonary infarctions, or major procedure-related adverse events were observed.

Conclusion: The LOBO device is a safe and effective tool for the embolization of PAVMs with persistent occlusion of the targeted lesion on medium-term follow-up. Larger, prospective, multi-center studies are warranted for further evaluation, including long-term efficacy.